Scientific Program
  • General Information
  • Welcome Message
  • Time Table
  • Scientific Program
  • Call for Abstract
  • Registration
  • Information for Participants
  • Access
  • Hotel & Tours
  • Link

Special Lectures

  1. Evaluation of clinical-grade induced Pluripotent Stem cells
    Kazutoshi Takahashi
    (Center for iPS Cell Research and Application, Kyoto University, Japan)
  2. Current Topics on Nonclinical Safety Assessment of Human Pharmaceuticals from an European Perspective.
    Jan Willem van der Laan
    (Pharmacology, Toxicology and Biotechnology Department, Medicines Evaluation Board, The Netherlands, Chair Safety Working Party)
  3. Medical innovation through the development of nanomaterials
    –Targeted cancer therapy by polymeric micelles–
    Kazunori Kataoka
    (Graduate School of Engineering/Graduate School of Medicine, the University of Tokyo, Japan)
  4. Assessment of Abuse Potential of Drugs: Translational Perspectives
    Jonathan L. Katz
    (Department of Pharmacology and Physiology, Drexel University School of Medicine, USA)
  5. Microglial Cells in CNS Immune Reactions and Their Response to Anti-Inflammatory Agents
    William F. Hickey
    (Department of Pathology/Department of Pharmacology & Toxicology, Geisel School of Medicine at Dartmouth, USA)

Educational Lectures

  1. Current Status and Issues of cancer vaccine development
    Tetsuya Nakatsura
    (Cancer Immunotherapy, National Cancer Center, Japan)
  2. Threshold of genotoxic carcinogens and challenges for their risk assessment
    Shoji Fukushima
    (Japan Bioassay Research Center, Japan Industrial Safety and Health Association, Japan)
  3. Issues and challenges in reproductive toxicity testing, including juvenile animal studies
    Kok Wah Hew
    (Global Drug Safety Research and Evaluation, Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited., USA)
  4. Toxicogenomics and Toxicogenetics: Genetic Diversity and Susceptibility to Toxicity in Next-Generation Human Health Risk Assessment
    Ivan Rusyn
    (Department of Environmental Sciences and Engineering, University of North Carolina at Chapel Hill, USA)
  5. Oligonucleotide Therapeutics: Is the Promise Ready to be Fulfilled?
    Arthur A. Levin
    (Avidity Nanomedicines, USA)
  6. Phospholipidosis: Histologic Finding or Histopathology?
    Kenneth L. Hastings
    (Sanofi US, USA)


  • Safety evaluation of vaccines
  • Toxicomics
  • Progress of MicroRNA Studies in Toxicology Research
  • Laboratory Animal Welfare and Animal Models: International Issues, Trends and Challenges
  • Application of Toxicogenomics and Future Perspectives
  • JSOT collaborating symposium with JSIT: New development of the innovative immunotoxicological investigations opening up by next generation
  • Progress of the study on non-CYP drug-metabolizing enzymes in drug development
    (Other 13 sessions)

Mini- Symposium

  • New doors for the field of prenatal and developmental toxicology
  • New environmental pollution and risk assessment
    (Other 2 sessions)


  • Challenge toward the risk minimization of adverse reactions through translational “imaging”
  • New Approach for Carcinogenicity Assessment of Pharmaceuticals
  • Paradigm shift for reproductive toxicity evaluation of Pharmaceuticals
    (Other 7 sessions)
Page Top